Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 11801 - 11825 of 12714 in total
Atamestane has been used in trials studying the treatment of Breast Cancer, Breast Neoplasms, and Neoplasms, Hormone-Dependent.
Investigational
Anagliptin is under investigation for the treatment of LDL Cholesterol, Coronary Disease, Diabetes Mellitus, Glycosylated Hemoglobin, and Dipeptidyl-Peptidase 4 Inhibitors.
Investigational
Matched Iupac: … N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine …
Acotiamide has been used in trials studying the treatment of Dyspepsia and Functional Dyspepsia.
Investigational
Matched Iupac: … N-{2-[bis(propan-2-yl)amino]ethyl}-2-(2-hydroxy-4,5-dimethoxybenzamido)-1,3-thiazole-4-carboxamide …
Cy 503 is under investigation in clinical trial NCT00658437 (Aviscumine for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy).
Investigational
Abituzumab has been used in trials studying the treatment of Prostate Cancer Metastatic.
Investigational
Investigational
Matched Iupac: … 2-[(6-chloropyridazin-3-yl)sulfanyl]-N,N-diethylacetamide …
Ansofaxine is under investigation in clinical trial NCT02271412 (Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005).
Investigational
Matched Iupac: … 4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate …
Anfibatide is under investigation in clinical trial NCT01585259 (Anfibatide Phase Ib-IIa Clinical Trial).
Investigational
Acolbifene is under investigation in clinical trial NCT01452373 (Dehydroepiandrosterone (DHEA) + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women).
Investigational
Matched Iupac: … (2S)-3-(4-hydroxyphenyl)-4-methyl-2-{4-[2-(piperidin-1-yl)ethoxy]phenyl}-2H-chromen-7-ol …
Adelmidrol is under investigation in clinical trial NCT01420510 (Saginil in vs. Placebo for Gynecologic Oncology Patients Affected by Vaginitis).
Investigational
Matched Iupac: … N,N'-bis(2-hydroxyethyl)nonanediamide …
VIT-100 was developed by ItherX Pharmaceuticals of San Diego. In preclinical studies, companyl has shown that VIT-100 inhibits the growth of cells taken from multiple keloid biopsies as compared to the same keloidal cells treated with a control. It is believed that similar effects would be seen in cells isolated...
Investigational
Matched Description: … growth of cells taken from multiple keloid biopsies as compared to the same keloidal cells treated with a
Niobium has been used in trials studying the treatment of Obesity and Overweight.
Investigational
LioCyx-M004 are autologous T cells transduced with a retroviral vector encoding a hepatitis B virus antigen-specific T cell receptor.
Investigational
Matched Description: … LioCyx-M004 are autologous T cells transduced with a retroviral vector encoding a hepatitis B virus antigen-specific …
Experimental
Matched Iupac: … 1-cyclohexyl-3-decylurea …
Experimental
Matched Iupac: … (2R)-5-methyl-2-[(1R)-2-oxo-1-[2-(thiophen-2-yl)acetamido]ethyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic …
Experimental
Matched Iupac: … (2R)-2-amino-3-{[(4-bromophenyl)methyl]sulfanyl}propanoic acid …
Chlorsulfaquinoxaline has been used in trials studying the treatment of Lung Cancer and Colorectal Cancer.
Investigational
Matched Iupac: … 4-amino-N-(5-chloroquinoxalin-2-yl)benzene-1-sulfonamide …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Experimental
Illicit
Experimental
Matched Iupac: … 2-[(4Z)-2-[(1S)-1,5-diaminopentyl]-4-[(4-hydroxyphenyl)methylidene]-5-oxo-4,5-dihydro-1H-imidazol-1-yl …
Experimental
Matched Iupac: … hexadecyltrimethylazanium (2S)-2-(6-methoxynaphthalen-2-yl)propanoate …
A group of compounds that are derivatives of heptanedioic acid with the general formula R-C7H11O4. [PubChem]
Experimental
Matched Description: … A group of compounds that are derivatives of heptanedioic acid with the general formula R-C7H11O4. …
Experimental
Matched Iupac: … (3R,4S,5S,6R)-6-({[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxane-2,3,4,5 …
AZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder. As of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared on the company’s development pipeline.
Investigational
Matched Description: … AZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive …
Displaying drugs 11801 - 11825 of 12714 in total